You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 4,559,330


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,559,330
Title: Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same
Abstract:A method of treating inflammatory diseases such as ulcerous colitis, comprising administration of 3,3'-azo-bis-(6-hydroxy benzoic acid) of the formula: ##STR1## or pharmaceutically acceptable salts thereof. Pharmaceutical compositions, especially for oral administration, contain said compound, or pharmaceutically acceptable salts thereof, together with pharmaceutically acceptable carriers and/or adjuvants.
Inventor(s): Agback; Karl H. (Uppsala, SE), Natvig; Tore (Uppsala, SE), Truelove; Sidney C. (Kirtlington, GB2)
Assignee: Pharmacia AB (Uppsala, SE)
Application Number:06/247,252
Patent Claims: 1. A method of treating inflammatory intestinal diseases, comprising administering to a patient in a need thereof therapeutically effective amount of 3,3'-azo-bis-(6-hydroxy benzoic acid) or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 comprising oral administration of said substance.

3. A method of treating ulcerous colitis, comprising administering to a patient in a need thereof a therapeutically effective amount of 3,3'-azo-bis-(6-hydroxy benzoic acid), or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 comprising oral administration of said substance.

5. A pharmaceutical composition comprising 3,3'-azo-bis-(6-hydroxy benzoic acid) or pharmaceutically acceptable salts thereof, in combination with at least one pharmaceutically acceptable carrier or adjuvant.

6. A composition for treating inflammatory intestinal diseases, comprising 3,3'-azo-bis-(6-hydroxy benzoic acid) or pharmaceutically acceptable salts thereof, in combination with at least one pharmaceutically acceptable carrier or adjuvant.

7. A composition for treating ulcerous colitis, comprising 3,3'-azo-bis-(6-hydroxy benzoic acid) or pharmaceutically acceptable salts thereof in combination with at least one pharmaceutically acceptable carrier or adjuvant.

8. An oral composition for treating inflammatory diseases in the large intestine, comprising 3,3'-azo-bis-(6-hydroxy benzoic acid) or pharmaceutically acceptable salts thereof, in combination with at least one pharmaceutically acceptable carrier or adjuvant.

9. A method according to claims 1 or 3 wherein said therapeutically effective amount is 0.5-10 g per day for adult patients.

10. A method according to claim 3 or claim 4 wherein said therapeutically effective amount is 0.5-10 g per day for adult patients.

11. A method according to claim 9 wherein said inflammatory intestinal diseases are in the large intestine.

12. A method according to any one of claims 1-4 wherein said salt is the disodium salt.

13. A composition according to any one of claims 5-8 and 9 wherein said salt is the disodium salt.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.